Evidence map›Paper›PMID 25574132›Full record

ArticleBiomarker insights2014

Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population.

Thomas H Haupt, Thomas Kallemose, Steen Ladelund, Line Jh Rasmussen, Christian W Thorball, Ove Andersen, Charlotta Pisinger, Jesper Eugen-Olsen

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarker insights, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06836141 (Silent Brain Infarcts in Spontaneous Intracerebral Hemorrhage as a Prognostic Biomarker for Vascular Contributions to Cognitive Impairment and Dementia), which is not on this map. Cited by 53 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 2 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06836141 recruitingnot on this mapstarted 2025, after this paper: background citation

Silent Brain Infarcts in Spontaneous Intracerebral Hemorrhage as a Prognostic Biomarker for Vascular Contributions to Cognitive Impairment and Dementia (VCID)

Typeobservational_patient_registrySponsorRush University Medical CenterRan2025 to 2029Enrolled118ConditionsPrimary Intracerebral HemorrhageArmsMRI, Blood Draw, Cognitive Test
3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Soluble urokinase plasminogen activator receptor biomarker is not a predictor of mortality in high-risk hip fracture patients.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2025
    Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Thomas H HauptClinical Research Centre, Department 056, Hvidovre Hospital, Hvidovre, Denmark.
Thomas KallemoseClinical Research Centre, Department 056, Hvidovre Hospital, Hvidovre, Denmark.
Steen LadelundClinical Research Centre, Department 056, Hvidovre Hospital, Hvidovre, Denmark.
Line Jh RasmussenClinical Research Centre, Department 056, Hvidovre Hospital, Hvidovre, Denmark.
Christian W ThorballClinical Research Centre, Department 056, Hvidovre Hospital, Hvidovre, Denmark.
Ove AndersenClinical Research Centre, Department 056, Hvidovre Hospital, Hvidovre, Denmark.
Charlotta PisingerResearch Centre for Prevention and Health, Department 84-85, Glostrup University Hospital, Glostrup, Denmark.
Jesper Eugen-OlsenClinical Research Centre, Department 056, Hvidovre Hospital, Hvidovre, Denmark.
Glostrup Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The soluble urokinase plasminogen activator receptor (suPAR) is a biomarker of mortality risk in various patient populations. However, little is known about the implications of lifestyle for suPAR levels in the general population. Lifestyle, demographic, and cardiovascular disease (CVD) risk factor data were collected from 5,538 participants in the Danish population-based Inter99 study. Their suPAR levels were measured using a sandwich enzyme-linked immunosorbent assay. In the final adjusted model, smoking and morbid obesity were strongly associated with higher suPAR levels (P < 0.001). An unhealthy diet and alcohol abstinence in men were also associated with higher suPAR levels. Physical activity in leisure time had a modest impact on suPAR levels in univariate analysis, but not in the final adjusted model. In conclusion, smoking and morbid obesity were strongly associated with higher serum suPAR levels in this general population. Diet and alcohol consumption also seemed to impact suPAR levels. Lifestyle changes are likely to affect suPAR since ex-smokers had suPAR levels comparable to those of never-smokers.

Indexed as

biomarkersepidemiologic studiesrisk factorsurokinase plasminogen activator receptor

Identifiers

PMID25574132
PMCPMC4269129
OpenAlexW2064139359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.